Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early detection and intervention in lupus nephritis at the American College of Rheumatology Convergence 2024. The findings emphasize the role of LUPKYNIS, a treatment for lupus nephritis, supported by robust clinical evidence. This highlights a need for proactive screening and management to prevent irreversible kidney damage in lupus patients.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
